Authors

C Parsy¹; 
¹ Oncodesign, France

Discussion

Molecular Radiotherapy (MRT) targeting SSTR2 or PSMA have proven to be highly efficient for treatment of neuroendocrine or metastatic prostate cancer respectively. Beyond the leading radiopharmaceutical molecules
177Lu-DOTATATE or 177Lu-PSMA-617, a variety of vectors (small molecules, peptides, panel of biologics)
have been developed on the same targets in order to improve the biodistribution within the tumor, the blood clearance, the route of elimination or the dosimetry.